TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Metformin in Association to Chemoradiotherapy for Locally Advanced Rectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older;~* biopsy proven poorly differentiated carcinoma or adenocarcinoma of the rectum;~* lesions located within 12 cm of the anal verge (from colonoscopy assessment);~* ability to tolerate oral treatment;~* locally advanced tumor, classified by the presence of positive regional lymph nodes or primary tumor invasion beyond the serosa (T3 or T4), assessed by MRI;~* eligibility for curative surgery (no distant metastasis or invasion of bony structures of the pelvis);~* Performance Status (PS) Eastern Cooperative Oncology Group (ECOG) 0-2;~* adequate hematologic functions (hemoglobin ≥ 10 g / dL \[5.6 mmol / L\]; neutrophil count ≥ 1,500 / mm3 and platelet count ≥ 100,000 / mm3), adequate renal function (serum creatinine less than 1.5 times the UNL) and adequate hepatic function (bilirubin less than 1.5 times the UNL; aspartate aminotransferase and alanine aminotransferase less than 2.5 times the UNL);~Exclusion Criteria:~* known hypersensitivity to metformin or its excipients;~* squamous carcinomas of the rectum or anal canal;~* chronic treatment with corticosteroids or other immunosuppressive agents;~* treatment with oral antidiabetic products;~* distant metastasis at diagnosis or tumor invasion of pelvic bone structures that may proscribe curative intent surgery;~* chronic or acute infections;~* use of drugs under study up to four weeks prior to randomization;~* pregnant or nursing patients;~* prior radiotherapy to the pelvic region;~* myocardial infarction up to six months prior to randomization, or uncontrolled ischemic heart disease;~* congestive heart insufficiency New York Heart Association (NYHA) III-IV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neoadjuvant capecitabine and metformin (Type: EXPERIMENTAL): * Capecitabine 825 mg/m2 bid D1-5, q7d, for five weeks;~* Metformin 2500mg/d for five weeks;~* 3D radiotherapy 50,4Gy divided in 25 fractions
- Neoadjuvant capecitabine and placebo (Type: PLACEBO_COMPARATOR): * Capecitabine 825 mg/m2 bid D1-5, q7d, for five weeks;~* Placebo 2500mg/d for five weeks;~* 3D radiotherapy 50,4Gy divided in 25 fractions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with AML, a certain type of ALL, NHL and MM~* certain types of cancer of the lymph nodes~* certain types of leukemias (blood cancers)~* disease has or will fail with other treatments~* relatively good overall health other than your cancer~Exclusion Criteria:~* poor bone marrow function (not producing enough blood cells)~* serious heart conditions~* poor liver or kidney function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Composite Cancellous and Demineralized Bone Plug (CR-Plug) for Repair of Knee Osteochondral Defects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 55 years~* skeletally mature~* Have a symptomatic score International Cartilage Repair Society (ICRS) grade 3a, 3b, 3c, 3d, 4a, 4b articular cartilage lesion less than 2.5 cm involving the Medial Femoral Condyle or Lateral Femoral Condyle. Symptoms must include pain, pain with weight bearing and squatting, locking of joints and or swelling~* Functional meniscal tissue (defined as 5 mmor greater)~* A score of = or greater than 4 on the VAS questionnaire~Exclusion Criteria:~* Associated tibial or patellar articular cartilage defect greater than 2 ICRS~* Osteoarthritis of either knee~* Mechanical axis malalignment of greater than 5 degrees~* Patellofemoral incongruity on Merchant view~* One or more multiple defects greater than 2.5 cm~* Osteochondritis dissecans (OCD) with depth of bone loss greater than 4 mm~* Ligament treatments in the affected knee within one year prior to current study~* Previous surgical meniscus treatment in the affected knee in the last 6 months~* Less than 5 mm of meniscal tissue in ipsilateral compartment of study treatment~* use of any investigational therapy within 30 days prior to the first visit~* Corticosteroid or viscosupplementation within the past 3 months~* A score of 3 or less on the VAS questionnaire~* Active gout or pseudogout or systemic inflammatory condition~* Microfracture less than one year prior to current study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Primary injury site (Type: OTHER): CR-Plug will be placed in the site of the primary injury
- Backfill site (Type: OTHER): Autograft will be placed in the site of the primary injury; CR Plug will be placed in the harvest site

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Caffeine Withdrawal on Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* migraine present for at least 1 year and fulfilling diagnostic criteria (ICHD-3 beta)~* =/\> 3 migraine attacks per month~* no migraine prophylaxis the last month~* consumption =/\> 300 mg and \</= 800 mg caffeine per day the last month~* signed consent~Exclusion Criteria:~* suspicion of medication-overuse headache~* pregnancy and breast feeding~* serious co-morbidity or conditions requiring Medical treatment or caution~* working night shift~* use of drugs with moderate or major interactions with caffeine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Caffeine (Type: ACTIVE_COMPARATOR): Caffeine tablets (Recip) 100 mg, 300-800 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: In Vitro Fertilization (IVF) and Acupuncture for Infertility

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* females between 21 and 42 years old~* primary or secondary infertility~* no more than 2 previously failed IVF cycles~* undergoing IVF~* FSH \< 11~Exclusion Criteria:~* FSH \> 11~* using an egg donor~* using PGD~* using heparin or lovanox protocols~* estradiol level less than 20 or over 80~* taking herbal therapy

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 42 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): IVF
- II (Type: OTHER): treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Study Of A Size Tailored Approach To Repair Umbilical And Epigastric Primary Ventral Hernias

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* all adult patients that are planned for surgical repair of a primary umbilical or epigastric hernia will be considered to enter the study.~Exclusion Criteria:~* patients refusing to participate at the follow up visits~* pregnancy~* age \< 18 years~* life expectancy less than 12 months~* recurrent umbilical or epigastric hernia~* incisional or trocar site hernias~* emergency operations~* liver cirrhosis or ascites~* cancer patients~* concomitant surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Rapid Assessment of Bedside BNP In Treatment of Heart Failure (RABBIT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Age 18 or older Patient was hospitalized and treated for heart failure Patient is fully stabilized at discharge Able to give informed consent~Exclusion Criteria:~History of severe pulmonary disease Chronic O2 therapy for COPD Primary pulmonary hypertension History of renal disease requiring dialysis History of severe hepatic disease Patients using LVAD's Stroke, MI, PTCA, CABG or unstable angina within the past 1 month Bi-ventricular pacemaker placement within last 1 month History of severe aortic stenosis History of severe mitral stenosis History of constrictive pericarditis Patient has had a cardiac transplant Status 1 cardiac transplant candidates ICD or DRG assignment of non-Q wave MI within last 1 month Patient has cor pulmonale A re-hospitalization, death or an IV treatment for heart failure before the first post-discharge visit and/or15) Planned chronic IV treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Investigation of the M2a-Magnum™ Hip System

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Non-inflammatory degenerative joint disease including: Avascular Necrosis, Diastrophic Variant, Fracture of the Pelvis, Fused Hip, Leg Perthes, Osteoarthritis, Slipped Capital Epiphysis, Subcapital Fractures, Traumatic Arthritis~* Rheumatoid Arthritis~* Correction of Functional Deformity~* Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques~* Revision of previously failed total hip arthroplasty~Exclusion Criteria:~Absolute contraindications include:~* Infection, Sepsis, and Osteomyelitis~Relative contraindications include:~* Uncooperative patient or patient with neurologic disorders that are incapable of following directions~* Osteoporosis~* Metabolic disorders which may impair bone formation~* Osteomalacia~* Distant foci of infections which may spread to the implant site~* Rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram~* Vascular insufficiency, muscular atrophy, or neuromuscular disease

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- M2a-Magnum™ Hip System (Type: None): Patients who received the M2a-Magnum™ Hip System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women with metastatic breast cancer who are completing planned course of chemotherapy with planned treatment break~* On stable hormone therapy for at least 2 months are also eligible for the study~* Estimated survival of at least 3 months~* No platelet inhibitor therapy within 1 month of study entry~* Platelets ≥ 100,000~* Coagulation screening tests within normal range (INR between 0.81 and 1.20)~* Normal kidney and liver function as defined by:~  * Aspartate aminotransferase(AST)/serum glutamic oxaloacetic transaminase (SGOT))/alanine aminotransferase(ALT) ≤ 2 x Institutional Normal~ * Creatinine ≤ 2 x Institutional Normal~* Able to provide signed, informed consent.~Exclusion Criteria:~* Patients going on to surgery~* Patients with a serious bleeding disorder that make them inappropriate candidates for NSAID therapy~* Patients with history of significant bleeding related to peptic ulcer disease~* Patients on standing doses of NSAIDS or platelet function inhibitors~* Patients on standing doses of anti-coagulants

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Plavix and Aspirin (Type: EXPERIMENTAL): Patients will receive a 300 mg loading dose of Plavix on day 1, followed by 75 mg/day, and aspirin 81 mg per day starting day 1. Treatment will be continued until the treating physician elects to resume systemic therapy for the treatment of breast cancer or until unacceptable toxicity is observed. A pill diary will be collected monthly to monitor patients' compliance with the medication regimen.
- Observation only (Type: NO_INTERVENTION): Observation by treating physician

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Rosiglitazone and Metformin: Outcomes Trial in Nondiabetic Patients With Stable Coronary Syndromes (Romance) Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient (male or non-pregnant female) must be \> 18 years of age.~* The patient or legally authorized representative must sign a written informed consent, prior to the procedure, using a form that is approved by the local Institutional Review Board.~* Angiographically documented coronary artery disease defined as the presence of at least one 50% or greater stenosis of a major coronary artery.~* Stabilized post any prior ACS event (i.e., without ongoing ischemic rest pain, congestive heart failure, or malignant arrhythmias) for at least 3 months~* Fasting blood glucose 87-125 mg/dL~Exclusion Criteria:~* Age \<18 years~* Known hypersensitivity to metformin or rosiglitazone~* Renal insufficiency defined as calculated creatinine clearance (CrCl) \<40 mL/min using the following formula:~Men: CrCL (mL/min) = Weight (kg) x (140-age) 72 x serum creatinine (mg/dL) Women: 0.85 x the value calculated for men~* Pregnant and/or lactating women, and women of child bearing potential are excluded from this trial~* Co-morbidity such that the patient is not expected to survive \>2 years~* Current therapy with rosiglitazone or metformin~* PCI within the previous six months (other than for the qualifying event)~* Prior CABG within the previous two months, scheduled CABG, or a decision to perform CABG made prior to enrollment~* Overt diabetes mellitus (FBG\>126 or antidiabetic therapy)~* Any diagnosis of congestive heart failure~* Obstructive hepatobiliary disease or other significant hepatic disease (defined as the presence of at least one of the following: AST, ALT, GGT, total bilirubin, or alkaline phosphatase \>3x upper limit normal, not related to MI~* Participation in any other clinical trials involving investigational or marketed products within 30 days prior to entry in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Avandamet (Type: ACTIVE_COMPARATOR): AVANDAMET 2/500 mg
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Catheter-Associated Urinary Tract Infection in Incontinence and Reconstructive Pelvic Surgery Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Requires catheterization \>24h hours following incontinence or pelvic reconstructive surgery~Exclusion Criteria:~* Receipt of antibiotics for either prophylaxis or treatment of a known infection during the postoperative hospitalization~* Allergy to sulfonamides or trimethoprim~* Non-English speaking~* Pregnancy~* Breast feeding~* Severe renal impairment (creatinine clearance \<30)~* Patients taking dofetilide, methenamine, procaine, warfarin, procainamide, methotrexate.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Drug (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Remote Incentives for Smoking Cessation Among AN Pregnant Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years of age~* report being smokers at the time they learned of the current pregnancy~* report smoking in the 7 days prior to completing their preliminary eligibility screening~* \< 25 weeks pregnant~* speak English~* own a smartphone (Android or iOS)~* self-report as an Alaska Native~* current smoker as verified by saliva cotinine test~Exclusion Criteria:~* current or prior mental or medical condition that may interfere with study participation~* smoke marijuana more than once each week and not willing to quit (marijuana smoking can inflate breath CO)~* exposed to unavoidable occupational sources of CO (e.g., car mechanic)~* report currently receiving opioid maintenance therapy (e.g., methadone, buprenorphine)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Best Practices + Incentives group (Type: EXPERIMENTAL): Participants assigned to this condition will receive the best practices treatment plus the financial incentives intervention.
- Best Practices (Type: ACTIVE_COMPARATOR): Participants assigned to this condition will receive the best practices treatment alone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gender Disparity in Burn Injury Survival

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men and women ages 18 to 65 years~* Admitted to University Medical Center with greater than 15% total body surface area burns~* Able to provide informed consent or has authorized representative to give informed consent~Exclusion Criteria:~* Prisoners or pregnant women~* Individuals with injuries that preclude taking caliper measurements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Women with burn injury (Type: None): None
- Men with burn injury (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of the Impact of Giant Cell Arteritis and Its Treatment on the Autonomy of the Elderly in the First Year of Care

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age greater than or equal to 65 years with at least 2 comorbidities \* present, or age greater than or equal to 75 years~* Diagnosis of ACG meeting the diagnostic criteria of ACG 1990 ACR~  * comorbidity = chronic pathology~Exclusion Criteria:~* Neoplastic pathology under treatment~* Brain pathology with motor disability~* Dementia at a severe stage (MMS \<22/30)~* Unable to answer the phone~* Participation in a therapeutic clinical trial

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- assessment by questionnaire (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues